iShares Biotechnology ETF (NASDAQ:IBB) Shares Acquired by TIAA Trust National Association

TIAA Trust National Association increased its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 33.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,154 shares of the financial services provider’s stock after acquiring an additional 787 shares during the period. TIAA Trust National Association’s holdings in iShares Biotechnology ETF were worth $417,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. TD Private Client Wealth LLC grew its position in shares of iShares Biotechnology ETF by 3.0% during the fourth quarter. TD Private Client Wealth LLC now owns 2,746 shares of the financial services provider’s stock worth $363,000 after buying an additional 81 shares in the last quarter. Cullen Frost Bankers Inc. lifted its position in shares of iShares Biotechnology ETF by 1.5% during the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock worth $748,000 after purchasing an additional 82 shares during the last quarter. Transcend Capital Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 0.8% during the fourth quarter. Transcend Capital Advisors LLC now owns 10,958 shares of the financial services provider’s stock worth $1,449,000 after purchasing an additional 92 shares in the last quarter. Chicago Partners Investment Group LLC increased its holdings in iShares Biotechnology ETF by 2.5% in the fourth quarter. Chicago Partners Investment Group LLC now owns 3,783 shares of the financial services provider’s stock valued at $510,000 after buying an additional 94 shares during the last quarter. Finally, WealthCare Investment Partners LLC raised its stake in iShares Biotechnology ETF by 0.9% in the fourth quarter. WealthCare Investment Partners LLC now owns 10,348 shares of the financial services provider’s stock valued at $1,375,000 after buying an additional 96 shares in the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

NASDAQ:IBB opened at $130.29 on Friday. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57. The stock has a market cap of $6.16 billion, a P/E ratio of 27.83 and a beta of 0.84. The stock has a 50-day simple moving average of $136.16 and a 200-day simple moving average of $138.96.

iShares Biotechnology ETF Increases Dividend

The firm also recently declared a dividend, which was paid on Friday, March 21st. Investors of record on Tuesday, March 18th were issued a $0.1212 dividend. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date of this dividend was Tuesday, March 18th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.